Company Profile
Jiangsu Sihuan Bioengineering provides the production and sales of biopharmaceutical products in China and globally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function.
Its portfolio also includes Xinlisheng, a human granulocyte colony-stimulating factor injection used to treat neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplastic anemia, and Huanerbo, a human erythropoietin injection used to treat symptoms, such as anemia caused by renal insufficiency. It is also involved in the provision of flower planting.
Its portfolio also includes forest and natural ecosystem management and protection, forest improvement, forestry product sales, Chinese herbal medicine planting, landscaping project construction, urban municipal greening management, scenic area management, municipal facilities management, earthwork construction, engineering management services, forest park management and design management, external contracting, project cost consulting services, and sale of metal material, agricultural and sideline product, and building and decoration material. Founded in 1992, Jiangsu Sihuan Bioengineering is headquartered in Jiangyin, China.